Streetbeat News

KZIA

Kazia Therapeutics Limited

https://www.kaziatherapeutics.com

Industry

Biotechnology

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Open

5.27

Mkt cap

16M

Volume

99K

High

5.41

P/E Ratio

-1.36

52-wk high

15.80

Low

4.30

Div yield

N/A

52-wk low

1.90

Trading for a certain asset was halted at 7:50:00 p.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 11:50 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. VSee Health (VSEE) saw a notable increase of 66.5%, while GRI Bio (GRI) rose by 21.58%. On the downside, SAB Biotherapeutics (SABS) fell by 7.8%, and Healthcare Triangle (HCTI) decreased by 7.21%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 8:31 pm

In Friday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (AMEX:VTAK) with a 151.9% increase, Akanda (NASDAQ:AKAN) up 71.13%, and Tenon Medical (NASDAQ:TNON) rising 39.06%. On the losing side, Orgenesis (NASDAQ:ORGS) fell 37.9%, Molecular Templates (NASDAQ:MTEM) dropped 30.11%, and NKGen Biotech (NASDAQ:NKGN) decreased by 29.02%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 12:09 pm

On Thursday, several health care stocks experienced significant intraday movements. Notable gainers included Tevogen Bio Holdings, Molecular Templates, and Kazia Therapeutics, while Biodexa Pharmaceuticals and 180 Life Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 4:31 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Prenetics Global, Chromocell Therapeutics, Nuwellis, MiNK Therapeutics, Accolade, and Tharimmune saw gains, while Trevena, Entero Therapeutics, NKGen Biotech, Kazia Therapeutics, Carmell, and Silexion Therapeutics experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:31 pm

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Theriva Biologics, Conduit Pharmaceuticals, and ENDRA Life Sciences were among the top gainers, while Windtree Therapeutics, Soligenix, and Kazia Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 12:06 pm

Kazia Therapeutics shares rose following the presentation of positive Phase I study data on paxalisib combined with radiation therapy for treating certain brain metastases at a major oncology conference.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 3:15 pm

Kazia Therapeutics presented promising Phase I data at the American Society for Radiation Oncology meeting, showing that treatment with paxalisib and radiotherapy achieved a 67% partial response in patients with brain metastases. This compares favorably to historical response rates for radiation therapy alone.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:48 pm

Kazia Therapeutics Limited (NASDAQ:KZIA) presented promising clinical data for EVT801, a VEGFR3 inhibitor, at the 15th Biennial Ovarian Cancer Research Symposium. The Phase 1 trial showed EVT801's safety and tolerability, with encouraging results in high grade serous ovarian cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:31 pm

Kazia Therapeutics shares rose following the announcement of a licensing agreement with QIMR Berghofer Medical Research Institute.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:49 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.